Dublin, June 27, 2019 (GLOBE NEWSWIRE) -- The "Bronchitol" report has been added to ResearchAndMarkets.com's offering.
Bronchitol is an inhaled dry powder formulation of mannitol, a naturally occurring monosaccharide that also acts as a mucolytic agent.
Once inhaled, Bronchitol has an osmotic effect that increases the hydration of airway surface liquid.
This facilitates mucociliary clearance in cystic fibrosis patients that have typically sticky mucus, alleviating some of the respiratory symptoms associated with the disease.
Key Topics Covered
- Drug Overview
- Product Profiles
- Bronchitol: Cystic fibrosis
List of Figures
Figure 1: Bronchitol for cystic fibrosis - SWOT analysis
Figure 2: The authors drug assessment summary of Bronchitol for cystic fibrosis
Figure 3: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country, 2016-25
List of Tables
Table 1: Bronchitol drug profile
Table 2: Bronchitol Phase III data in cystic fibrosis
Table 3: Bronchitol sales for cystic fibrosis across the US, Germany, and the UK, by country ($m), 2016-25
For more information about this report visit https://www.researchandmarkets.com/r/mg55n8
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.